Skip to content
Preprint · OA via OpenAlex

mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner

Basavaraju G. Sanganahalli, Jelena M. Mihailovic, Hemendra J. Vekaria, Daniel Coman, Andrew T. Yackzan, Abeoseh Flemister, Chetan B. Aware, Kathryn Wenger, W. Brad Hubbard, Patrick G. Sullivan, Fahmeed Hyder, Ai‐Ling Lin

Journal of Cerebral Blood Flow & Metabolism · 2024 · ▲ 12 citations

Abstract

Apolipoprotein ε4 (APOE4) carriers develop brain metabolic dysfunctions decades before the onset of Alzheimer’s disease (AD). A goal of the study is to identify if mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), an inhibitor for the mammalian target of rapamycin (mTOR) inhibitor, would enhance synaptic and mitochondrial function in asymptomatic mice with human APOE4 gene (E4FAD) before they showed metabolic deficits. A second goal is to determine whether there may be genetic-dependent responses to rapamycin when compared to mice with human APOE3 alleles (E3FAD), a neutral AD genetic risk factor. We fed asymptomatic E4FAD and E3FAD mice with control or rapamycin diets for 16 weeks from starting from 3 months of age. Neuronal mitochondrial oxidative metabolism and excitatory neurotransmission rates were measured using in vivo 1 H-[ 13 C] proton-observed carbon-edited magnetic resonance spectroscopy, and isolated mitochondrial bioenergetic measurements using Seahorse. We found that rapamycin enhanced neuronal mitochondrial function, glutamate-glutamine cycling, and TCA cycle rates in the asymptomatic E4FAD mice. In contrast, rapamycin enhances glycolysis, non-neuronal activities, and inhibitory neurotransmission of the E3FAD mice. These findings indicate that rapamycin might be able to mitigate the risk for AD by enhancing brain metabolic functions for cognitively intact APOE4 carriers, and the responses to rapamycin are varied by APOE genotypes. Consideration of precision medicine may be needed for future rapamycin therapeutics.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1177/0271678x241261942
Canonical
link ↗
Fetched
2026-11-14 MST

Cite this

APA
Sanganahalli, B.G., Mihailovic, J.M., Vekaria, H.J., Coman, D., Yackzan, A.T., Flemister, A., Aware, C.B., Wenger, K., Hubbard, W.B., Sullivan, P.G., Hyder, F., &amp; Lin, A. (2024). mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner. <em>Journal of Cerebral Blood Flow & Metabolism</em>. https://doi.org/10.1177/0271678x241261942
Vancouver
Sanganahalli BG, Mihailovic JM, Vekaria HJ, Coman D, Yackzan AT, Flemister A, et al. mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner. Journal of Cerebral Blood Flow & Metabolism. 2024. doi:10.1177/0271678x241261942.
BibTeX
@unpublished{basavaraju2024mTORin, title = {mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner}, author = {Basavaraju G. Sanganahalli and Jelena M. Mihailovic and Hemendra J. Vekaria and Daniel Coman and Andrew T. Yackzan and Abeoseh Flemister and Chetan B. Aware and Kathryn Wenger and W. Brad Hubbard and Patrick G. Sullivan and Fahmeed Hyder and Ai‐Ling Lin}, journal = {Journal of Cerebral Blood Flow & Metabolism}, year = {2024}, doi = {10.1177/0271678x241261942}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings